LUCD

$1.38

Pre-MarketAs of Mar 17, 8:00 PM UTC

Lucid Diagnostics Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.38
Potential Upside
5%
Whystock Fair Value$1.45
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and canc...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$180.92M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-331.24%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.87

Recent News

Zacks
Mar 17, 2026

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -22.73% and +7.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 3, 2026

908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates

908 Devices (MASS) delivered earnings and revenue surprises of +11.82% and +4.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 26, 2026

Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of +30.06% and +1.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 24, 2026

Orthofix (OFIX) Q4 Earnings and Revenues Lag Estimates

Orthofix (OFIX) delivered earnings and revenue surprises of -40.91% and -0.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 12, 2026

Inogen (INGN) Soars 6.6%: Is Further Upside Left in the Stock?

Inogen (INGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BEARISH
Negative press. News cycle fixated on risk factors or misses.